Effect of semaglutide on kidney function across different levels of baseline HbA1c, blood pressure, body weight and albuminuria in SUSTAIN 6 and PIONEER 6.
Publication Title
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Document Type
Article
Publication Date
7-2-2024
Keywords
cardiovascular risk; diabetes; eGFR decline; semaglutide; washington; spokane
Abstract
BACKGROUND AND HYPOTHESIS: This post-hoc analysis explored the semaglutide effects on eGFR slope by baseline glycemic control, blood pressure (BP), body mass index (BMI), and albuminuria status in people with type 2 diabetes and high cardiovascular risk.
METHODS: Pooled SUSTAIN 6 and PIONEER 6 data were analyzed for change in estimated glomerular filtration (eGFR) slope by baseline HbA1c (<8%/≥8%;300 mg/g).
RESULTS: The estimated absolute treatment differences (ETD) overall in eGFR slope [95% confidence intervals] favored semaglutide versus placebo in the pooled analysis (0.59 [0.29;0.89] mL/min/1.73m2/year) and in SUSTAIN 6 (0.60 [0.24;0.96] mL/min/1.73m2/year); the absolute benefit was consistent across all HbA1c, BP, BMI, and UACR subgroups (all p-interaction > 0.5).
CONCLUSION: A clinically meaningful reduction in risk of chronic kidney disease progression was observed with semaglutide versus placebo regardless of HbA1c, BP, BMI, and UACR levels.
Clinical Institute
Kidney & Diabetes
Clinical Institute
Digestive Health
Specialty/Research Institute
Nephrology
Specialty/Research Institute
Endocrinology
Specialty/Research Institute
Gastroenterology
DOI
10.1093/ndt/gfae150
